Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671949 | 0.88 | CES2 (0.52) | CES2CES1KMT2AHDAC6THRA | |
| SCHEMBL3670856 | 0.86 | CES2 (0.50) | CES2CES1KMT2AHDAC6THRA | |
| SCHEMBL10031827 | 0.82 | PGR (0.47) | CES2CES1PGRARALDH1A1 | |
| SCHEMBL11655940 | 0.82 | HDAC6 (0.47) | KMT2AHDAC6PGRARTHRA | |
| SCHEMBL11817087 | 0.81 | CES2 (0.46) | CES2CES1KMT2AHDAC6THRA | |
| SCHEMBL1628100 | 0.81 | ALDH1A1 (0.59) | ALDH1A1PLK1LMNA | |
| SCHEMBL8242799 | 0.81 | EPHX2 (0.50) | KMT2AHDAC6PGRARTHRA | |
| SCHEMBL10587459 | 0.80 | PGR (0.41) | CES2CES1KMT2AHDAC6PGR | |
| Hydrochloric Acid SCHEMBL11651072 | 0.80 | HDAC6 (0.46) | KMT2AHDAC6PGRARTHRA | |
| SCHEMBL13389977 | 0.79 | THRA (0.59) | KMT2AHDAC6PGRARTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014198478-A2 | BIFUNCTIONAL CHELATING AGENTS BASED ON THE 1,4-DIAZEPINE SCAFFOLD (DAZA) FOR NON-INVASIVE MOLECULAR IMAGING | Johannes Gutenberg-Universität Mainz (DE) | 2014-12-18 | — | — | WO | disclosed |
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| US-5319123-A | Reacting an N-alkoxyamide with an acyl halide in the presence of a hindered base | SANDOZ LTD. (CH) | 1994-06-07 | — | — | US | disclosed |
| EP-0234045-B1 | A PYRAZOLE OXIME DERIVATIVE AND ITS PRODUCTION AND USE | NIHON NOHYAKU CO., LTD. (JP) | 1992-09-02 | — | — | EP | disclosed |
| US-4011344-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-4006248-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1977-02-01 | — | — | US | disclosed |
| US-4000307-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1976-12-28 | — | — | US | disclosed |
| US-3996286-A | HYPOLIPIDEMIC AGENTS, HYPOCHOLESTEROLEMICS | SANDOZ, INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3978132-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1976-08-31 | — | — | US | disclosed |
| US-3978132-A | HYPOLIPIDEMIC | SANDOZ, INC. (US) | 1976-08-31 | — | — | US | disclosed |
| US-3962342-A | Bromination process | SANDOZ, INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962342-A | Bromination process | SANDOZ, INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3962320-A | HYPOLIPIDEMIC AGENTS | SANDOZ, INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3919323-A | Acyl substituted dibenzylethers | SANDOZ AG | 1975-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | CES2 1412/4885CES1 1306/4885KMT2A 2390/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | CES2 1285/4885CES1 1184/4885KMT2A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.